EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent

N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies

WC Jackson, J Silva, HE Hartman, RT Dess… - International Journal of …, 2019 - Elsevier
Purpose Utilization of stereotactic body radiation therapy (SBRT) for treatment of localized
prostate cancer is increasing. Guidelines and payers variably support the use of prostate …

[HTML][HTML] Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised …

AC Tree, P Ostler, H van der Voet, W Chu… - The Lancet …, 2022 - thelancet.com
Background Localised prostate cancer is commonly treated with external beam radiotherapy
and moderate hypofractionation is non-inferior to longer schedules. Stereotactic body …

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 …

A Widmark, A Gunnlaugsson, L Beckman… - The Lancet, 2019 - thelancet.com
Background Hypofractionated radiotherapy for prostate cancer has gained increased
attention due to its proposed high radiation-fraction sensitivity. Recent reports from studies …

[HTML][HTML] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - thelancet.com
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent

N Mottet, J Bellmunt, M Bolla, E Briers… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …

Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer

CN Catton, H Lukka, CS Gu, JM Martin… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Men with localized prostate cancer often are treated with external radiotherapy (RT)
over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per …

Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer

AU Kishan, A Dang, AJ Katz, CA Mantz… - JAMA network …, 2019 - jamanetwork.com
Importance Stereotactic body radiotherapy harnesses improvements in technology to allow
the completion of a course of external beam radiotherapy treatment for prostate cancer in the …

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised …

P Fransson, P Nilsson, A Gunnlaugsson… - The Lancet …, 2021 - thelancet.com
Summary Background The HYPO-RT-PC trial compared conventionally fractionated
radiotherapy with ultra-hypofractionated radiotherapy in patients with localised prostate …

[HTML][HTML] Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial

DA Hamstra, N Mariados, J Sylvester, D Shah… - International Journal of …, 2017 - Elsevier
Purpose SpaceOAR, a Food and Drug Administration–approved hydrogel intended to create
a rectal–prostate space, was evaluated in a single-blind phase III trial of image guided …